Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pain, Postoperative 9Breast Neoplasms 6Brain Neoplasms 6Neoplasms 4Lung Neoplasms 4Thyroid Neoplasms 3Agnosia 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Pheochromocytoma 2Neoplasm Metastasis 2Liver Neoplasms 2Dexmedetomidine 2Colonic Neoplasms 2Chronic Pain 2Supratentorial Neoplasms 1Sleep Initiation and Maintenance Disorders 1Sigmoid Neoplasms 1Seizures 1Prostatic Hyperplasia 1Postoperative Nausea and Vomiting 1Postoperative Analgesia 1Pneumoperitoneum 1Pancreatic Neoplasms 1Pain, Intractable 1Obesity 1Neuroinflammatory Diseases 1Neurofibromatoses 1

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 4pimonidazole 2TH 302 2gadobutrol 1fluoromisonidazole 1Surgical Procedures, Operative 1Sodium Chloride 1Sevoflurane 1Saline Solution 1Radiotherapy 1Propofol 1Positron Emission Tomography Computed Tomography 1Pancreaticoduodenectomy 1Oxygen 1NVP-BKM120 1Ketamine 1Gemcitabine 1Ferrosoferric Oxide 1Dexmedetomidine 1Blood Specimen Collection 1Biopsy 1Bacterial Load 1Atovaquone 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hypoxia × Dexmedetomidine × Clear all
NCT04266665 2026-03-25

Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome

Aristotle University Of Thessaloniki

Phase 4 Completed
56 enrolled
CNS

Neuroinflammatory Diseases, Hypoxia, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡